8-K Announcements
6Material company update
Apr 1, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Dec 31, 2025·SEC
Aldeyra Therapeutics, Inc.(ALDX)Earnings, Financials & Key Ratios
ALDX•NASDAQ
$1.74
$105M mkt cap·Price updated May 6, 2026
AboutAldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.Show more
- Revenue$0
- EBITDA-$60M-40.8%
- Net Income-$56M-48.8%
- EPS (Diluted)-0.94-46.9%
- ROE-58.54%-111.1%
- ROIC-369.42%+11.9%
- Debt/Equity0.22+64.9%
- Interest Coverage-31.21-51.0%
ALDX Key Insights
Aldeyra Therapeutics, Inc. (ALDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALDX Price & Volume
Aldeyra Therapeutics, Inc. (ALDX) stock price & volume — 10-year historical chart
Loading chart...
ALDX Growth Metrics
Aldeyra Therapeutics, Inc. (ALDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM2.71%
Return on Capital
10 Years-57.4%
5 Years-41.75%
3 Years-39.46%
Last Year-56.7%
ALDX Recent Earnings
Aldeyra Therapeutics, Inc. (ALDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 0/12 qtrs (0%)
Q1 2026Latest
Feb 27, 2026EPS
$0.11
Est $0.14
+21.4%
Revenue
—
Est $5M
Q4 2025
Nov 5, 2025EPS
$0.13
Est $0.17
+23.5%
Revenue
—
Est $24M
Q3 2025
Aug 7, 2025EPS
$0.16
Est $0.21
+23.8%
Revenue
—
Q2 2025
May 14, 2025EPS
$0.17
Est $0.25
+32.0%
Revenue
—
Est $666,670
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 27, 2026 | $0.11vs $0.14+21.4% | —vs $5M |
| Q4 2025 | Nov 5, 2025 | $0.13vs $0.17+23.5% | —vs $24M |
| Q3 2025 | Aug 7, 2025 | $0.16vs $0.21+23.8% | — |
| Q2 2025 | May 14, 2025 | $0.17vs $0.25+32.0% | —vs $666,670 |
Based on last 12 quarters of dataView full earnings history →
ALDX Peer Comparison
Aldeyra Therapeutics, Inc. (ALDX) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 2.11B | 9.71 | -6.84 | -18.67% | -5.58% | -64.55% | 0.12 | |
 KALA | 855.53K | 0.12 | -0.02 | -141.11% | -388.29% | 2.62 | ||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 SRRK | 5.41B | 47.07 | -14.31 | -145.91% | 0.44 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 RXST | 279.79M | 6.78 | -7.14 | -3.89% | -36.58% | -17.01% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 TARS | 2.76B | 64.76 | -40.73 | 146.71% | -9.02% | -14.19% | 0.27 |
Compare ALDX vs Peers
Aldeyra Therapeutics, Inc. (ALDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALDX Income Statement
Aldeyra Therapeutics, Inc. (ALDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 37.85K | 71K | 96.31K | 56.22K | 0 | 0 | 0 | 0 | 64.37K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -35.79K▲ 0% | -37.85K▼ 5.7% | -71K▼ 87.6% | -96.31K▼ 35.6% | -56.22K▲ 41.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -64.37K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -90.61% | -5.75% | -87.6% | -35.64% | 41.62% | 100% | - | - | - | - |
| Operating Expenses | 18.7M | 22.49M | 39.7M | 56.51M | 34.61M | 56.22M | 62.68M | 42.79M | 60.12M | 45.11M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.52M | 6.19M | 9.88M | 12.15M | 9.93M | 11.28M | 15.37M | 13.34M | 11.89M | 9.12M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 13.18M | 16.3M | 29.82M | 44.35M | 24.68M | 44.94M | 47.31M | 29.46M | 48.22M | 35.99M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.7M▲ 0% | -22.49M▼ 20.3% | -39.7M▼ 76.5% | -63.07M▼ 58.9% | -34.67M▲ 45.0% | -56.22M▼ 62.2% | -62.68M▼ 11.5% | -42.79M▲ 31.7% | -60.12M▼ 40.5% | -45.18M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -55.94% | -20.28% | -76.53% | -58.88% | 45.04% | -62.17% | -11.49% | 31.73% | -40.48% | - |
| EBITDA | -18.66M | -22.45M | -39.63M | -62.98M | -34.61M | -55.96M | -62.42M | -42.53M | -59.87M | -44.92M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -55.89% | -20.31% | -76.52% | -58.92% | 45.04% | -61.67% | -11.56% | 31.86% | -40.76% | 9.03% |
| D&A (Non-Cash Add-back) | 35.79K | 37.85K | 71K | 96.31K | 56.22K | 264.18K | 258.71K | 262.78K | 249.62K | 251.25K |
| EBIT | -18.59M | -22.23M | -38.75M | -61.53M | -36.13M | -56.03M | -60.33M | -35.47M | -53.93M | -41.29M |
| Net Interest Income | -3.47K | 147.8K | 805.91K | 937.5K | -1.61M | -1.56M | 655.35K | 5.25M | 4.27M | 1.98M |
| Interest Income | 102.04K | 261.25K | 952.7K | 1.54M | 292.22K | 185.36K | 2.35M | 7.32M | 6.19M | 3.88M |
| Interest Expense | 105.51K | 113.45K | 146.79K | 603.85K | 1.9M | 1.74M | 1.69M | 2.07M | 1.93M | 1.9M |
| Other Income/Expense | -3.47K | 147.8K | 805.91K | 0 | -3.37M | -1.56M | 655.35K | 5.25M | 4.27M | 1.98M |
| Pretax Income | -18.7M▲ 0% | -22.34M▼ 19.5% | -38.89M▼ 74.1% | -62.14M▼ 59.8% | -38.03M▲ 38.8% | -57.78M▼ 51.9% | -62.02M▼ 7.4% | -37.54M▲ 39.5% | -55.85M▼ 48.8% | -43.19M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 66.25K | 223.4K | 0 | -1.31M | -479.26K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.35% | -1% | 0% | 2.11% | 1.26% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.7M▲ 0% | -22.34M▼ 19.5% | -38.89M▼ 74.1% | -60.83M▼ 56.4% | -37.55M▲ 38.3% | -57.78M▼ 53.8% | -62.02M▼ 7.4% | -37.54M▲ 39.5% | -55.85M▼ 48.8% | -43.19M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -54.66% | -19.48% | -74.09% | -56.4% | 38.26% | -53.85% | -7.35% | 39.47% | -48.77% | 3.58% |
| Net Income (Continuing) | -18.7M | -22.34M | -38.89M | -60.83M | -37.55M | -57.78M | -62.02M | -37.54M | -55.85M | -43.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.65▲ 0% | -1.40▲ 15.2% | -1.79▼ 27.9% | -2.24▼ 25.1% | -1.11▲ 50.4% | -1.07▲ 3.6% | -1.06▲ 0.9% | -0.64▲ 39.6% | -0.94▼ 46.9% | -0.72▲ 0% |
| EPS Growth % | -17.86% | 15.15% | -27.86% | -25.14% | 50.45% | 3.6% | 0.93% | 39.62% | -46.88% | 2.71% |
| EPS (Basic) | -1.65 | -1.40 | -1.79 | -2.24 | -1.11 | -1.07 | -1.06 | -0.64 | -0.94 | - |
| Diluted Shares Outstanding | 11.35M | 15.92M | 21.69M | 27.11M | 33.97M | 54.04M | 58.41M | 58.94M | 59.48M | 60.13M |
| Basic Shares Outstanding | 11.35M | 15.92M | 21.69M | 27.11M | 33.97M | 54.04M | 58.41M | 58.94M | 59.48M | 60.13M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ALDX Balance Sheet
Aldeyra Therapeutics, Inc. (ALDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 25.13M | 43.97M | 94.77M | 75.17M | 83.06M | 232.75M | 181.02M | 147.81M | 104.07M | 77.46M |
| Cash & Short-Term Investments | 24.91M | 42.95M | 93.6M | 73.36M | 77.86M | 229.79M | 174.3M | 142.82M | 101.15M | 75.3M |
| Cash Only | 12.02M | 20.02M | 47.36M | 44.43M | 77.86M | 229.79M | 144.42M | 142.82M | 54.53M | 59.34M |
| Short-Term Investments | 12.9M | 22.92M | 46.24M | 28.94M | 0 | 0 | 29.88M | 0 | 46.62M | 15.96M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 28.77K | 3.24M | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 1.4M | 4.79M | 2.5M | 3.05M | 4.65M | 2.51M | 2.16M |
| Total Non-Current Assets | 56.35K | 209.19K | 321.87K | 349.46K | 293.24K | 384.35K | 268.54K | 516.58K | 534.22K | 340.98K |
| Property, Plant & Equipment | 56.35K | 43.26K | 235.22K | 349.46K | 293.24K | 384.35K | 268.54K | 516.58K | 266.95K | 340.98K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 165.93K | 86.64K | 0 | 0 | 0 | 0 | 0 | 267.26K | 267.26K |
| Total Assets | 25.19M▲ 0% | 44.17M▲ 75.4% | 95.09M▲ 115.3% | 75.52M▼ 20.6% | 83.35M▲ 10.4% | 233.14M▲ 179.7% | 181.29M▼ 22.2% | 148.33M▼ 18.2% | 104.61M▼ 29.5% | 77.8M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -10.7% | 75.38% | 115.26% | -20.58% | 10.37% | 179.7% | -22.24% | -18.18% | -29.48% | -129.8% |
| Total Current Liabilities | 2.3M | 3.35M | 8.47M | 12.91M | 12.41M | 11.77M | 15.36M | 22.26M | 18.6M | 28.48M |
| Accounts Payable | 275.44K | 1M | 3.05M | 808.3K | 381.64K | 1.02M | 133.63K | 1.34M | 180.45K | 13.42K |
| Days Payables Outstanding | - | 9.65K | 15.69K | 3.06K | 2.48K | - | - | - | - | 2.83K |
| Short-Term Debt | 77.55K | 116.32K | 0 | 0 | 3.66M | 0 | 911.76K | 15.15M | 31.37K | 15.47M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6M | 24M |
| Other Current Liabilities | 983.45K | 788.57K | 1.17M | 1.49M | 1.32M | 1.51M | 3.82M | 3.09M | 4.33M | 7.01M |
| Current Ratio | 10.93x | 13.11x | 11.18x | 5.82x | 6.69x | 19.77x | 11.78x | 6.64x | 5.59x | 5.59x |
| Quick Ratio | 10.93x | 13.11x | 11.18x | 5.82x | 6.69x | 19.77x | 11.78x | 6.64x | 5.59x | 5.59x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.24M | 1.22M | 0 | 14.53M | 11.43M | 15.63M | 14.92M | 6.27M | 15M | 72.54K |
| Long-Term Debt | 1.24M | 1.22M | 0 | 14.53M | 11.43M | 15.5M | 14.92M | 0 | 15M | 72.54K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 125.23K | 0 | 271.63K | 0 | 356.22K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.54M | 4.57M | 8.47M | 27.44M | 23.84M | 27.4M | 30.28M | 28.53M | 33.6M | 28.56M |
| Total Debt | 1.32M | 1.34M | 0 | 14.75M | 15.33M | 15.86M | 16.08M | 15.66M | 15.3M | 15.54M |
| Net Debt | -10.7M | -18.69M | -47.36M | -29.67M | -62.53M | -213.93M | -128.34M | -127.17M | -39.22M | -43.8M |
| Debt / Equity | 0.06x | 0.03x | - | 0.31x | 0.26x | 0.08x | 0.11x | 0.13x | 0.22x | 0.22x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.35x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.97x |
| Interest Coverage | -177.20x | -198.21x | -270.44x | -104.45x | -18.21x | -32.27x | -37.00x | -20.66x | -31.21x | -21.72x |
| Total Equity | 21.65M▲ 0% | 39.6M▲ 82.9% | 86.62M▲ 118.7% | 48.08M▼ 44.5% | 59.51M▲ 23.8% | 205.74M▲ 245.7% | 151.01M▼ 26.6% | 119.8M▼ 20.7% | 71M▼ 40.7% | 49.24M▲ 0% |
| Equity Growth % | -12.98% | 82.92% | 118.73% | -44.49% | 23.76% | 245.72% | -26.6% | -20.67% | -40.73% | -170.55% |
| Book Value per Share | 1.91 | 2.49 | 3.99 | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | 1.19 | 0.82 |
| Total Shareholders' Equity | 21.65M | 39.6M | 86.62M | 48.08M | 59.51M | 205.74M | 151.01M | 119.8M | 71M | 49.24M |
| Common Stock | 12.58K | 19.14K | 26.24K | 28.66K | 38.67K | 58.08K | 58.56K | 59.2K | 59.65K | 60.16K |
| Retained Earnings | -77.3M | -99.64M | -138.54M | -199.36M | -236.92M | -294.69M | -356.72M | -394.26M | -450.11M | -477.5M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 129 | -17.83K | -9.22K | 5.87K | 0 | 0 | -103.94K | 0 | 37.44K | 815 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALDX Cash Flow Statement
Aldeyra Therapeutics, Inc. (ALDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.15M | -19.22M | -29.86M | -44.98M | -37.49M | -42.56M | -56.64M | -30.33M | -43.21M | -43.21M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -62.67% | -26.9% | -55.32% | -50.66% | 16.65% | -13.5% | -33.09% | 46.46% | -42.48% | -2483.03% |
| Net Income | -18.7M | -22.34M | -38.89M | -60.83M | -37.55M | -57.78M | -62.02M | -37.54M | -55.85M | -43.19M |
| Depreciation & Amortization | 35.79K | 37.85K | 71K | 96.31K | 56.22K | 264.18K | 258.71K | 262.78K | 249.62K | 251.25K |
| Stock-Based Compensation | 2.76M | 2.71M | 4.14M | 8.08M | 7.08M | 7.11M | 8.29M | 5.75M | 7.97M | 6.26M |
| Deferred Taxes | 266.11K | 129.25K | -237.54K | -1.31M | -479.26K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 27.31K | 20.34K | 59.32K | 6.23M | 2.23M | 409.47K | 283.9K | 339.65K | -1.49M | -1.09M |
| Working Capital Changes | 462.97K | 215.45K | 5M | 2.74M | -8.83M | 7.44M | -3.44M | 861.18K | 5.91M | -2.31M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -575.72K | 725.52K | 2.05M | -2.85M | -426.66K | 638.06K | -886.08K | 1.2M | -1.16M | -173.5K |
| Cash from Investing | -225.23K | -10.2M | -23.34M | 18.48M | 29.02M | -7.81K | -29.95M | 30M | -44.92M | 30.17M |
| Capital Expenditures | -11.81K | -24.76K | -262.97K | -9.53K | 0 | -7.81K | -16.32K | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 11.81K | 24.76B | 262.97B | 609.46K | 0 | 0 | 16.32K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -11.81K | -24.76B | -262.97B | 0 | 0 | 0 | -16.32K | 0 | 0 | 0 |
| Cash from Financing | 12.74M | 37.43M | 80.53M | 23.58M | 41.9M | 194.5M | 1.22M | -1.27M | -171.42K | 1.13M |
| Debt Issued (Net) | 0 | 0 | 0 | 14.45M | 0 | 0 | 0 | -1.04M | -292.5K | -292.5K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 305.23K | 121.08K | 1.42M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -165.93K | -1.4M | 1.23M | 1.19M | 4.68M | 0 | -532.95K | 0 | 0 |
| Net Change in Cash | -2.63M▲ 0% | 8.01M▲ 404.1% | 27.33M▲ 241.3% | -2.93M▼ 110.7% | 33.43M▲ 1240.4% | 151.93M▲ 354.4% | -85.37M▼ 156.2% | -1.6M▲ 98.1% | -88.3M▼ 5431.1% | -8.78M▲ 0% |
| Free Cash Flow | -15.16M▲ 0% | -19.25M▼ 27.0% | -30.12M▼ 56.5% | -44.99M▼ 49.4% | -37.49M▲ 16.7% | -42.56M▼ 13.5% | -56.65M▼ 33.1% | -30.33M▲ 46.5% | -43.21M▼ 42.5% | -40.08M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -61.31% | -26.97% | -56.49% | -49.38% | 16.67% | -13.52% | -33.1% | 46.47% | -42.48% | -30.69% |
| FCF per Share | -1.34 | -1.21 | -1.39 | -1.66 | -1.10 | -0.79 | -0.97 | -0.51 | -0.73 | -0.73 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.86x | 0.77x | 0.74x | 1.00x | 0.74x | 0.91x | 0.81x | 0.77x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 850.13K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALDX Key Ratios
Aldeyra Therapeutics, Inc. (ALDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -80.38% | -72.95% | -61.63% | -90.31% | -69.81% | -43.56% | -34.77% | -27.73% | -58.54% | -87.71% |
| Return on Invested Capital (ROIC) | -124.81% | -105.86% | -98.96% | -164.05% | -337.91% | - | -649.5% | -419.49% | -369.42% | -369.42% |
| Debt / Equity | 0.06x | 0.03x | - | 0.31x | 0.26x | 0.08x | 0.11x | 0.13x | 0.22x | 0.22x |
| Interest Coverage | -177.20x | -198.21x | -270.44x | -104.45x | -18.21x | -32.27x | -37.00x | -20.66x | -31.21x | -21.72x |
| FCF Conversion | 0.81x | 0.86x | 0.77x | 0.74x | 1.00x | 0.74x | 0.91x | 0.81x | 0.77x | 0.93x |
ALDX SEC Filings & Documents
Aldeyra Therapeutics, Inc. (ALDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALDX Frequently Asked Questions
Aldeyra Therapeutics, Inc. (ALDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aldeyra Therapeutics, Inc. (ALDX) grew revenue by 0.0% over the past year. Growth has been modest.
Aldeyra Therapeutics, Inc. (ALDX) reported a net loss of $43.2M for fiscal year 2024.
Dividend & Returns
Aldeyra Therapeutics, Inc. (ALDX) has a return on equity (ROE) of -58.5%. Negative ROE indicates the company is unprofitable.
Aldeyra Therapeutics, Inc. (ALDX) had negative free cash flow of $40.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More ALDX
Aldeyra Therapeutics, Inc. (ALDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates